2025年全球乳癌診斷市場報告

預計未來幾年乳癌診斷市場規模將強勁成長。到 2029 年，這一數字將成長至 69.1 億美元，複合年成長率為 8.2%。預測期內的成長預計將歸因於個人化醫療、液態切片、3D乳房X光攝影（斷層合成）、人工智慧和機器學習、遠端醫療和遠距諮詢。預測期內的關鍵趨勢包括影像技術、個人化醫療、液態切片以及人工智慧和機器學習的進步。

預計乳癌診斷市場的成長將受到乳癌發病率上升的推動。乳癌是最常見的癌症，每年影響約210萬名女性，並導致女性癌症死亡人數最多，預計將增加對診斷設備的需求。早期發現對於改善乳癌預後和降低死亡率至關重要。例如，2022年1月，美國癌症協會報告稱，2022年美國女性預計將新增287,850例浸潤性乳癌病例和51,400例DCIS病例，並有43,250例乳癌相關死亡病例。因此，乳癌發生率的上升預計將推動乳癌診斷市場的發展。

政府針對乳癌的措施和資金將促進乳癌診斷市場的成長。政府透過措施和財政支持在推動乳癌研究、預防和治療方面發揮著至關重要的作用。這些計畫旨在提高人們對乳癌的認知，透過篩檢和乳房X光攝影服務促進早期發現，並為服務不足的社區提供乳癌檢測和治療的經濟援助。在 2022-23 年預算中，澳洲政府衛生署已撥款 4,070 萬美元用於改善多種癌症的檢測和篩檢服務，其中包括 970 萬美元的專案預算用於乳癌篩檢。因此，政府措施和資金籌措投入正在推動乳癌診斷市場向前發展。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、新冠疫情、經濟復甦對市場的影響

第5章 全球成長分析與策略分析框架

• 全球乳癌診斷PESTEL分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
• 最終用途產業分析
• 全球乳癌診斷市場：成長率分析
• 全球乳癌診斷市場表現：規模與成長，2019-2024
• 全球乳癌診斷市場預測：規模與成長，2024-2029 年，2034 年
• 全球乳癌診斷總目標市場（TAM）

第6章市場區隔

• 全球乳癌診斷市場類型、績效及預測（2019-2024 年、2024-2029 年及 2034 年）
• 影像學診斷
• 切片檢查
• 基因組檢測
• 血液檢查
• 其他類型
• 全球乳癌診斷市場（按技術、效能和預測），2019-2024 年、2024-2029 年、2034 年
• 螢光原位雜合反應（FISH）
• 比較基因組雜合反應（CGH）
• 免疫組織化學（IHC）
• 其他技術
• 全球乳癌診斷市場（按癌症類型、表現和預測）：2019-2024 年、2024-2029 年、2034 年
• BRCA乳癌
• ER和PR乳癌
• HER2乳癌
• 乳癌EGFR突變檢測
• 其他類型的癌症
• 全球乳癌診斷市場按診斷類型、表現和預測，2019-2024 年、2024-2029 年、2034 年
• 電離乳房成像技術
• 非電離成像技術
• 全球乳癌診斷市場：按最終用戶、績效和預測，2019-2024 年、2024-2029 年、2034 年
• 醫院和診所
• 癌症研究中心
• 診斷實驗室
• 門診手術中心
• 全球乳癌診斷市場、影像細分市場、類型、績效及預測（2019-2024 年、2024-2029 年及 2034 年）
• 乳房X光檢查
• 超音波影像
• 磁振造影（MRI）
• 正子斷層掃描（PET）
• 斷層合成
• 全球乳癌診斷市場，依切片檢查類型細分，績效及預測，2019-2024 年、2024-2029 年、2034 年
• 針吸切片
• 芯針切片
• 細針抽吸切片檢查（FNA）
• 立體定位切片檢查
• 全球乳癌診斷市場依基因組檢測類型、績效及預測細分，2019-2024 年、2024-2029 年、2034 年
• Oncotype DX
• 媽媽印花
• PAM50
• BRCA1或2檢測
• 全球乳癌診斷市場按血液檢測類型、表現和預測細分，2019-2024 年、2024-2029 年、2034 年
• 液態生物檢體
• 循環腫瘤DNA（ctDNA）檢測
• 循環性腫瘤細胞(CTC) 檢測
• 全球乳癌診斷市場，按類型細分，實際及預測，2019-2024 年、2024-2029 年、2034 年
• 荷爾蒙受體檢測
• HER2檢測
• 基因突變檢測

第7章 區域和國家分析

• 全球乳癌診斷市場：按地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
• 全球乳癌診斷市場：依國家、表現及預測，2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章 澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章 德國市場

第18章 法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章競爭格局與公司概況

• 乳癌診斷市場：競爭格局
• 乳癌診斷市場：公司簡介
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Hologic Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Koninklijke Philips NV Overview, Products and Services, Strategy and Financial Analysis
  • Fujifilm Holdings Corporation Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型創新企業

• GE Healthcare
• Thermo Fisher Scientific Inc.
• Siemens AG
• NanoString Technologies Inc.
• Gamma Medica Inc.
• Aurora Imaging Technology Inc.
• Dilon Technologies Inc.
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd
• Micrima Limited
• Provista Diagnostics Inc.
• Leica Biosystems Nussloch GmbH
• bioTheranostics Inc.
• Bio-Rad Laboratories Inc.
• Illumina Inc.

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章 高市場潛力國家、細分市場與策略

• 2029年乳癌診斷市場：提供新機會的國家
• 2029年乳癌診斷市場：細分領域帶來新機會
• 2029年乳癌診斷市場：成長策略
  • 基於市場趨勢的策略
  • 競爭對手的策略

第36章 附錄

Breast cancer is a medical condition characterized by the uncontrolled proliferation of cells within the breast, often leading to the formation of lumps. Breast cancer diagnostic devices are designed for the purpose of identifying and confirming the presence of cancerous growth within the breast tissue.

Key categories within breast cancer diagnostics include various diagnostic methods such as imaging techniques, biopsies, genomic testing, blood tests, and other relevant approaches. Biopsy, a process involving the removal of tissue or cellular samples from the body for subsequent laboratory testing, is one of the primary diagnostic techniques employed in breast cancer cases. The technologies utilized for these diagnostic procedures encompass Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC) techniques, along with others. Breast cancer exhibits diverse types, including BRCA breast cancer, ER and PR breast cancer, HER2-positive breast cancer, EGFR mutation test breast cancer, and additional variants. Breast cancer diagnostics are further categorized into ionizing breast imaging technologies and non-ionizing imaging technologies. The end-users of these diagnostic services encompass hospitals and clinics, cancer research centers, diagnostic laboratories, as well as ambulatory surgical centers.

The breast cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides breast cancer diagnostics market statistics, including breast cancer diagnostics industry global market size, regional shares, competitors with a breast cancer diagnostics market share, detailed breast cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer diagnostics industry. This breast cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The breast cancer diagnostics market size has grown strongly in recent years. It will grow from $4.68 billion in 2024 to $5.04 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to awareness and screening campaigns, mammography screening, technological advancements, genetic testing, multidisciplinary approach.

The breast cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $6.91 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to personalized medicine, liquid biopsies, 3d mammography (tomosynthesis), ai and machine learning, telemedicine and remote consultations. Major trends in the forecast period include advancements in imaging technologies, personalized medicine, liquid biopsies, ai and machine learning.

The growth of the breast cancer diagnostics market is expected to be driven by the increasing incidence of breast cancer. With breast cancer being the most prevalent form of cancer, affecting approximately 2.1 million women annually and resulting in the highest number of cancer-related deaths among women, the demand for diagnostic equipment is set to rise. Early detection is paramount in improving the prognosis and reducing the mortality rate associated with breast cancer. For example, in January 2022, the American Cancer Society reported an estimated 287,850 new cases of invasive breast cancer and 51,400 cases of DCIS in women in the United States for 2022, with an expected 43,250 breast cancer-related fatalities. Hence, the escalating incidence of breast cancer is projected to fuel the breast cancer diagnostics market.

Government initiatives and funding for breast cancer are poised to contribute to the growth of the breast cancer diagnostics market. Government support, through initiatives and financial backing, plays a crucial role in advancing breast cancer research, prevention, and treatment. These programs aim to raise awareness, promote early detection through screening and mammography services, and provide financial aid for underserved communities undergoing breast cancer testing and treatment. In the budget for 2022-23, the Australian Government Department of Health allocated $40.7 million to improve the accessibility of testing and screening services for various cancer types, including a dedicated $9.7 million for breast cancer screening. Consequently, government initiatives and funding initiatives are propelling the breast cancer diagnostics market forward.

In the breast cancer diagnostics market, a significant trend is the continuous advancement in technology, which has led to the development of new diagnostic techniques for breast cancer. One notable innovation is 3D mammography, also known as breast tomosynthesis, which captures multiple images of the breast from various angles and constructs a 3-D model. An example of technological innovation in this field is the introduction of Thermalytix by Niramai, an Indian Health-Tech company, in September 2022. Thermalytix is an automated breast cancer screening and diagnostic tool that combines thermal imaging with artificial intelligence to enhance breast cancer detection and diagnosis.

Key players in the breast cancer diagnostics market are actively engaged in the development of cutting-edge AI-based devices designed to improve diagnostic accuracy and drive market revenues. AI breast cancer diagnostic devices leverage artificial intelligence algorithms to analyze complex medical data and offer valuable diagnostic insights and recommendations. By applying machine learning and data processing techniques, these devices can deliver highly accurate and efficient disease identification. For example, Digistain, a biotech company based in the United Kingdom, launched an AI breast cancer diagnostic tool in December 2022, boasting an accuracy rate of over 99%. This technology, validated through clinical studies and peer reviews, not only expedites diagnoses but also enhances treatment decisions. It holds the potential to significantly reduce waiting times, lower costs, and enable personalized risk assessment, potentially eliminating the need for chemotherapy in some cases. Through the application of machine learning and proprietary optical scans, this device can identify intricate patterns that traditional methods may overlook, providing highly personalized risk evaluations validated with a substantial patient sample.

In July 2024, Hologic Inc., a US-based healthcare technology company, acquired Endomagnetics Ltd. for $310 million. This acquisition allows Hologic to strengthen its breast surgery portfolio by integrating Endomag's innovative wireless localization and lymphatic tracing technologies. Endomagnetics Ltd., based in the UK, specializes in advanced breast cancer diagnostic solutions, including technologies for tissue localization and lymphatic tracing.

Major companies operating in the breast cancer diagnostics market include Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Epigenomics AG, AstraZeneca plc, Quest Diagnostics Incorporated, Agilent Technologies Inc., Cepheid, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Oncocyte Corporation, PerkinElmer Inc., Sysmex Corporation, Veracyte Inc.

North America was the largest region in the breast cancer diagnostics market in 2024. Asia-Pacific was the second largest region in the breast cancer diagnostics industry. The regions covered in the breast cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the broadband internet services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The breast cancer diagnostics market consists of sales of instruments such as analyzer, reagents and others that are used for the diagnosis of breast cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Breast Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on breast cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for breast cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The breast cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Imaging; Biopsy; Genomic Tests; Blood Tests; Other Types
• 2) By Technology: Fluorescent In Situ Hybridization (FISH); Comparative Genomic Hybridization (CGH); Immunohistochemical (IHC); Other Technologies
• 3) By Cancer Type: BRCA Breast Cancer; ER And PR Breast Cancer; HER 2 Breast Cancer; EGFR Mutation Test Breast Cancer; Other Cancer Types
• 4) By Diagnostic Type: Ionizing Breast Imaging Technologies; Non-ionizing Imaging Technologies
• 5) By End Users: Hospitals And Clinics; Cancer Research Centers; Diagnostic Laboratories; Ambulatory Surgical Centers
• Subsegments:
• 1) By Imaging: Mammography; Ultrasound Imaging; Magnetic Resonance Imaging (MRI); Positron Emission Tomography (PET); Tomosynthesis
• 2) By Biopsy: Needle Biopsy; Core Needle Biopsy; Fine Needle Aspiration Biopsy (FNA); Stereotactic Biopsy
• 3) By Genomic Tests: Oncotype DX; MammaPrint; PAM50; BRCA1 Or 2 Testing
• 4) By Blood Tests: Liquid Biopsy; Circulating Tumor DNA (ctDNA) Tests; Circulating Tumor Cells (CTCs) Tests
• 5) By Other Types: Hormone Receptor Tests; HER2 Tests; Genetic Mutation Testing
• Companies Mentioned: Abbott Laboratories; Myriad Genetics Inc.; Hologic Inc.; Koninklijke Philips N.V.; Fujifilm Holdings Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Breast Cancer Diagnostics Market Characteristics

3. Breast Cancer Diagnostics Market Trends And Strategies

4. Breast Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Breast Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Breast Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Breast Cancer Diagnostics Market Growth Rate Analysis
• 5.4. Global Breast Cancer Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Breast Cancer Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Breast Cancer Diagnostics Total Addressable Market (TAM)

6. Breast Cancer Diagnostics Market Segmentation

• 6.1. Global Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Imaging
• Biopsy
• Genomic Tests
• Blood Tests
• Other Types
• 6.2. Global Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fluorescent In Situ Hybridization (FISH)
• Comparative Genomic Hybridization (CGH)
• Immunohistochemical (IHC)
• Other Technologies
• 6.3. Global Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• BRCA Breast Cancer
• ER And PR Breast Cancer
• HER 2 Breast Cancer
• EGFR Mutation Test Breast Cancer
• Other Cancer Types
• 6.4. Global Breast Cancer Diagnostics Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ionizing Breast Imaging Technologies
• Non-ionizing Imaging Technologies
• 6.5. Global Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Cancer Research Centers
• Diagnostic Laboratories
• Ambulatory Surgical Centers
• 6.6. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Imaging, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mammography
• Ultrasound Imaging
• Magnetic Resonance Imaging (MRI)
• Positron Emission Tomography (PET)
• Tomosynthesis
• 6.7. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Biopsy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Needle Biopsy
• Core Needle Biopsy
• Fine Needle Aspiration Biopsy (FNA)
• Stereotactic Biopsy
• 6.8. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Genomic Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncotype DX
• MammaPrint
• PAM50
• BRCA1 Or 2 Testing
• 6.9. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Blood Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Liquid Biopsy
• Circulating Tumor DNA (ctDNA) Tests
• Circulating Tumor Cells (CTCs) Tests
• 6.10. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormone Receptor Tests
• HER2 Tests
• Genetic Mutation Testing

7. Breast Cancer Diagnostics Market Regional And Country Analysis

• 7.1. Global Breast Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Breast Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Breast Cancer Diagnostics Market

• 8.1. Asia-Pacific Breast Cancer Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Breast Cancer Diagnostics Market

• 9.1. China Breast Cancer Diagnostics Market Overview
• 9.2. China Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Breast Cancer Diagnostics Market

• 10.1. India Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Breast Cancer Diagnostics Market

• 11.1. Japan Breast Cancer Diagnostics Market Overview
• 11.2. Japan Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Breast Cancer Diagnostics Market

• 12.1. Australia Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Breast Cancer Diagnostics Market

• 13.1. Indonesia Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Breast Cancer Diagnostics Market

• 14.1. South Korea Breast Cancer Diagnostics Market Overview
• 14.2. South Korea Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Breast Cancer Diagnostics Market

• 15.1. Western Europe Breast Cancer Diagnostics Market Overview
• 15.2. Western Europe Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Breast Cancer Diagnostics Market

• 16.1. UK Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Breast Cancer Diagnostics Market

• 17.1. Germany Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Breast Cancer Diagnostics Market

• 18.1. France Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Breast Cancer Diagnostics Market

• 19.1. Italy Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Breast Cancer Diagnostics Market

• 20.1. Spain Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Breast Cancer Diagnostics Market

• 21.1. Eastern Europe Breast Cancer Diagnostics Market Overview
• 21.2. Eastern Europe Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Breast Cancer Diagnostics Market

• 22.1. Russia Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Breast Cancer Diagnostics Market

• 23.1. North America Breast Cancer Diagnostics Market Overview
• 23.2. North America Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Breast Cancer Diagnostics Market

• 24.1. USA Breast Cancer Diagnostics Market Overview
• 24.2. USA Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Breast Cancer Diagnostics Market

• 25.1. Canada Breast Cancer Diagnostics Market Overview
• 25.2. Canada Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Breast Cancer Diagnostics Market

• 26.1. South America Breast Cancer Diagnostics Market Overview
• 26.2. South America Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Breast Cancer Diagnostics Market

• 27.1. Brazil Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Breast Cancer Diagnostics Market

• 28.1. Middle East Breast Cancer Diagnostics Market Overview
• 28.2. Middle East Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Breast Cancer Diagnostics Market

• 29.1. Africa Breast Cancer Diagnostics Market Overview
• 29.2. Africa Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Breast Cancer Diagnostics Market Competitive Landscape And Company Profiles

• 30.1. Breast Cancer Diagnostics Market Competitive Landscape
• 30.2. Breast Cancer Diagnostics Market Company Profiles
  • 30.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Hologic Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Koninklijke Philips N.V. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Fujifilm Holdings Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Breast Cancer Diagnostics Market Other Major And Innovative Companies

• 31.1. GE Healthcare
• 31.2. Thermo Fisher Scientific Inc.
• 31.3. Siemens AG
• 31.4. NanoString Technologies Inc.
• 31.5. Gamma Medica Inc.
• 31.6. Aurora Imaging Technology Inc.
• 31.7. Dilon Technologies Inc.
• 31.8. Exact Sciences Corporation
• 31.9. F. Hoffmann-La Roche Ltd
• 31.10. Micrima Limited
• 31.11. Provista Diagnostics Inc.
• 31.12. Leica Biosystems Nussloch GmbH
• 31.13. bioTheranostics Inc.
• 31.14. Bio-Rad Laboratories Inc.
• 31.15. Illumina Inc.

32. Global Breast Cancer Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Breast Cancer Diagnostics Market

34. Recent Developments In The Breast Cancer Diagnostics Market

35. Breast Cancer Diagnostics Market High Potential Countries, Segments and Strategies

• 35.1 Breast Cancer Diagnostics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Breast Cancer Diagnostics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Breast Cancer Diagnostics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer